A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
NCT05651932
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is trying to find out if a new medicine is safe for adults with a type of cancer called multiple myeloma. The medicine is a small molecule that can stop a protein called MMSET from working in the body. The scientists want to see if this medicine can help keep the cancer from coming back or getting worse. They will give the medicine to people who have already had other treatments for their cancer but it did not work.
This study is trying to find out if a new medicine is safe for adults with a type of cancer called multiple myeloma. The medicine is a small molecule that can stop a protein called MMSET from working in the body. The scientists want to see if this medicine can help keep the cancer from coming back or getting worse. They will give the medicine to people who have already had other treatments for their cancer but it did not work.
Third Opinion AI Generated Synopsis
Trial Summary
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
